Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “sector perform” rating reaffirmed by equities research analysts at RBC Capital Markets in a research report issued on Tuesday.

A number of other equities analysts have also recently weighed in on the stock. Deutsche Bank AG began coverage on shares of Valeant Pharmaceuticals International in a research report on Tuesday. They set a “hold” rating and a $30.00 price target on the stock. Wells Fargo & Co. reissued a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Sunday. Morgan Stanley reissued an “overweight” rating and set a $42.00 price target on shares of Valeant Pharmaceuticals International in a research report on Wednesday, September 7th. Piper Jaffray Cos. set a $22.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “sell” rating in a research report on Friday, August 19th. Finally, Canaccord Genuity reissued a “hold” rating and set a $33.00 price target (up from $31.00) on shares of Valeant Pharmaceuticals International in a research report on Friday, August 19th. Six equities research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has an average rating of “Hold” and a consensus target price of $56.09.

Shares of Valeant Pharmaceuticals International (NYSE:VRX) traded down 2.269% during midday trading on Tuesday, reaching $26.485. 9,235,576 shares of the company were exchanged. The stock has a 50-day moving average price of $27.50 and a 200 day moving average price of $29.38. Valeant Pharmaceuticals International has a 52-week low of $18.55 and a 52-week high of $225.54. The company’s market capitalization is $9.20 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/rbc-capital-markets-reiterates-sector-perform-rating-for-valeant-pharmaceuticals-international-inc-vrx.html

Valeant Pharmaceuticals International (NYSE:VRX) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 earnings per share for the quarter, missing analysts’ consensus estimates of $1.48 by $0.08. The firm had revenue of $2.42 billion for the quarter, compared to the consensus estimate of $2.47 billion. Valeant Pharmaceuticals International had a positive return on equity of 46.59% and a negative net margin of 9.29%. The company’s revenue for the quarter was down 11.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.14 earnings per share. Equities research analysts expect that Valeant Pharmaceuticals International will post $6.54 EPS for the current fiscal year.

In other Valeant Pharmaceuticals International news, Director Argeris N. Karabelas purchased 4,000 shares of the firm’s stock in a transaction on Thursday, August 11th. The stock was purchased at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the transaction, the director now owns 20,726 shares in the company, valued at approximately $510,895.90. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 16.37% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $108,000. Tobam boosted its position in shares of Valeant Pharmaceuticals International by 127.5% in the first quarter. Tobam now owns 439,700 shares of the specialty pharmaceutical company’s stock valued at $11,575,000 after buying an additional 246,400 shares during the period. Howard Hughes Medical Institute boosted its position in shares of Valeant Pharmaceuticals International by 61.5% in the first quarter. Howard Hughes Medical Institute now owns 10,871 shares of the specialty pharmaceutical company’s stock valued at $286,000 after buying an additional 4,141 shares during the period. BlackRock Group LTD acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $3,340,000. Finally, Franklin Resources Inc. boosted its position in shares of Valeant Pharmaceuticals International by 29.9% in the first quarter. Franklin Resources Inc. now owns 377,843 shares of the specialty pharmaceutical company’s stock valued at $9,932,000 after buying an additional 86,959 shares during the period. Hedge funds and other institutional investors own 63.60% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.